Haisco Pharmaceutical Group Co. Ltd. has described compounds acting as TNF-α/tumor necrosis factor receptor superfamily member 1A (TNFR1) interaction inhibitors reported to be useful for the treatment of psoriasis, Crohn’s disease, ulcerative colitis and rheumatoid arthritis.
Shenzhen Targetrx Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to Raf kinase B (V600E mutant)-targeting moiety through linker reported to be useful for the treatment of cancer.
Researchers at Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have identified 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer, fibrosis, cerebral ischemia, depression, sleep disorders, Parkinson’s disease, immunological disorders and inflammatory disorders, among others.
China Pharmaceutical University has synthesized transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer, fibrosis, metabolic diseases and inflammatory disorders.
Jiangsu Simcere Biologics Co. Ltd. has disclosed antibody-drug conjugates (ADC) comprising an antibody huAb-H3aL3-IgG1 targeting cadherin-17 (CDH17) covalently linked to a camptothecin derivative through a linker reported to be useful for the treatment of cancer.
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab), Merck & Co. Inc.’s reigning blockbuster cancer drug.
Laekna Pharmaceutical Ningbo Co. Ltd. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Shanghai Xianxiang Medical Technology Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety coupled to an EGFR (HER1; erbB1) mutant-targeting moiety through a linker reported to be useful for the treatment of cancer.
RSS
